Singapore markets closed

Straits Times Index
3,290.70
+24.75(+0.76%)
Nikkei
38,229.11
+155.13(+0.41%)
Hang Seng
18,963.68
+425.87(+2.30%)
FTSE 100
8,433.76
+52.41(+0.63%)
Bitcoin USD
60,577.97
-1,872.80(-3.00%)
CMC Crypto 200
1,302.78
-55.23(-4.07%)

REGN Jan 2025 980.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

56.80

0.00

(0.00%)

As of 03:12PM EDT. Market open.

Simply Wall St.
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
Key Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant...
Thomson Reuters StreetEvents
Q1 2024 Intellia Therapeutics Inc Earnings Call
Q1 2024 Intellia Therapeutics Inc Earnings Call
GlobeNewswire
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) wi